From terminology and regulatory category through to safety checks — what to sort out before you decide
Getting the Term “Regenerative Medicine” Straight First
Regenerative medicine is a term used very broadly. Treatments that use cells, research into stem cells, techniques for building tissue, and the products actually in clinical use can all end up discussed under the same heading. Sorting out how these differ makes everything else far easier to compare.
What regenerative medicine refers to
Broadly, regenerative medicine describes a field of medicine that uses cells, tissue and related technologies with the aim of helping damaged tissue or organs recover. What sets it apart is that it looks beyond drugs and surgery to the behaviour of cells and the rebuilding of tissue.
The span it covers, though, is wide — from work still at the research stage through to treatments using products that have received national approval.
How the related terms differ
Cell therapy
The approach of introducing cells themselves into the body with the aim of recovery or regulation. It is often described as one part of regenerative medicine.
Stem cell research
Research into stem cells, which have the property of developing into various cell types. It may lead to future treatments, but research and available treatment need to be kept separate in your thinking.
Tissue engineering
Techniques that combine cells, materials and design principles to build or supplement tissue. It is one of the foundational technologies underpinning regenerative medicine.
Regenerative medical products1
Among products made by processing human or animal cells, those handled under Japan’s Pharmaceuticals and Medical Devices Act as approved regenerative medical products. Cell products into which genes are introduced and expressed also fall within this category. Unlike research materials, they are used according to their approved indications, dosage and administration.
1. On “regenerative medical products”
This is a statutory category under Japan’s Act on Pharmaceuticals and Medical Devices. It is specific to the Japanese regulatory system and does not map directly onto categories used in other countries.
Ways of telling them apart, to keep in mind
- —Separate out whether this is “research” or “treatment”
- —Look not only at whether cells are used, but under which regulatory framework it is carried out
- —Don’t conflate stem cells, cultured cells, tissue and products
- —Check whether the explanation states the intended conditions and purpose specifically
How to read the terminology when you encounter it
When a brochure or explanatory document says “regenerative,” “cells” or “stem cells,” it doesn’t automatically mean the same thing each time. Reading each layer separately — which cells are used, research or treatment, approved product or not — makes the information much easier to organise.
Regenerative medicine draws attention as a newer option, but the ground it covers is genuinely broad. Getting the terminology clear first makes the later work of checking regulation and safety considerably smoother.
Clinical Research, Approved Treatment and Self-Funded Care: What Separates Them
When considering regenerative medicine, working out which of these three it falls under is the critical first step. The regulatory category changes what gets explained to you, how costs work, and which documents you should be checking.
| Category | Regulatory position | How to identify it |
|---|---|---|
| Clinical research | A verification stage for confirming efficacy and safety. It isn’t something to receive as though it were ordinary care; it follows a research protocol. | Check whether the research purpose, eligibility criteria, consent documents, who bears the cost, and the registry are all set out. |
| Approved treatment | Treatment using regenerative medical products, or related care, that has passed national review. The conditions treated and how it is used are defined. | Look at whether approval status, indications, dosage and conditions of use have been explained. |
| Self-funded care2 | Care provided outside public insurance, with costs borne by the patient. Content differs by facility, and the same name does not mean the same method. | Check which cells and processing are used, whether it is approved or unapproved, and whether the total cost is stated. |
2. On “self-funded care”
This corresponds to the Japanese term jiyu shinryo — care that falls outside Japan’s public health insurance, with the full cost borne by the patient.
Clinical research is a framework for verifying effect
In clinical research, the procedure isn’t applied uniformly to everyone: participants and steps are decided in advance. Whether the study is registered, whether the research purpose is stated in the explanatory documents, and what happens if you withdraw partway through are all important things to confirm.
Because it is at the verification stage, research results shouldn’t be read the same way as results from established treatment.
Approved treatment has been through national review
For approved treatment, the conditions covered and the method of use of regenerative medical products are clearly defined. These products have been approved as products made using cell processing and similar methods, and are distinct from research materials or unapproved procedures.
When it’s explained to you, look beyond whether approval exists and confirm whether your own condition falls within the approved indications.
Self-funded care varies widely between facilities
Because self-funded care sits outside insured care, the same words “regenerative medicine” can cover entirely different cells, processing methods, explanatory materials and pricing from one facility to the next.
Some do use approved products, but being self-funded does not automatically mean the method has been standardised. The regulatory category and what is actually done need to be confirmed separately.
Self-funded care still has statutory procedures
Wide variation between facilities does not mean self-funded care sits in an unregulated space. In Japan, providing regenerative medicine using processed cells — whether as clinical research or as self-funded care — falls under the Act on the Safety of Regenerative Medicine, and medical institutions are required to complete set procedures. Three things offer a useful handle when checking the regulatory position.
Provision plan
Whether a plan has been submitted to the Ministry of Health, Labour and Welfare. Submitted plans are published by the Ministry.
Certified committee review
Provision plans are required to pass review by a committee certified by the Minister of Health, Labour and Welfare.
Cell processing facility
Manufacture of specified processed cells is subject to notification and licensing requirements under the same Act.
Having completed these procedures does not mean the state has guaranteed the treatment works. It indicates only whether care is being provided within the statutory framework. Efficacy and suitability still need to be explained and confirmed separately.
A checklist for telling them apart
- —Is this clinical research, approved treatment, or self-funded care?
- —Are the conditions or symptoms it addresses described specifically?
- —If a regenerative medical product is used, can you tell whether it is approved?
- —Are costs, consent documents and explanatory materials presented separately and clearly?
A knack for reading the regulatory differences
A description may say “regenerative medicine,” but the meaning shifts depending on whether it is research, approved treatment or self-funded care. Identify the category first, then compare content and cost — in that order, the information falls into place.
Once you have these three distinctions, it becomes much clearer what to ask when something is being explained to you. Rather than judging by the impression a term gives, reading from the regulatory position is the first step in understanding regenerative medicine.
Safety and Risk: What to Confirm Beforehand
In regenerative medicine, how safety should be considered changes with the process from collection through processing to administration, the type of cells used, and the route of administration. Alongside efficacy, it matters to confirm in advance the possible side effects and complications, and how the explanation is given.
Start with “what could happen”
Safety in regenerative medicine is not uniform across treatments. Pain or bleeding at the collection site, management issues during processing, swelling, fever or allergic reaction after administration — the risks that apply differ by method.
What needs confirming isn’t only the cells themselves, but also the collection, the technique, anaesthesia and any medication involved.
What to look for in a risk explanation
- —Are the anticipated side effects explained specifically?
- —Are frequency and severity given, as far as they are known?
- —Is there a response plan and a contact route if something occurs?
- —Is there an explanation of what happens if it doesn’t work?
An explanation that stops at “it’s safe” or “there are hardly any side effects” may not be complete. Individual variation, medical history and current medications all change what needs watching, so confirm which conditions apply to you.
What to ask at each stage: collection, processing, administration
Collection
Confirm the possibility of infection, pain or bruising at the collection site.
Processing (where applicable)
How it is managed within the facility, what happens if something is abnormal, and how quality is verified.
Administration
Intravenous, intra-articular and local injection are different techniques, each with its own complication profile.
Rather than judging by the name of the treatment, asking about the actual steps gives you far more to go on.
What to watch for during the explanation
Beyond whether written documentation exists, notice whether the verbal explanation matches the treatment content, and whether your questions get specific answers. If anything remains unresolved, don’t decide on the spot — go back and check again.
What to tell them about your condition
Existing conditions, allergy history, use of immunosuppressants, any infection, and the possibility of pregnancy can all affect safety. Give an accurate account of your medical history and current condition, and confirm with your doctor whether you meet the conditions for treatment.
What to Check When Choosing a Medical Provider
When comparing providers, it helps to look past the impression a treatment name gives and examine specifics: how clearly things are explained, the reasoning behind suitability, how care is delivered, and how transparent the process is. Compare calmly, within what materials and consultations actually let you verify.
A checklist before your appointment
Is the intended patient clear?
Which conditions are envisaged, and is there an explanation of who falls outside them?
Are the materials readable?
Beyond technical terms, are the treatment process, points to confirm and consent steps organised?
Is the delivery structure visible?
Can you see who handles diagnosis, testing, collection, processing, administration and follow-up?
Is the regulatory category distinguished?
Does the explanation separate clinical research, approved treatment and self-funded care?
Is the process transparent?
Can you confirm the cost breakdown, number of visits and availability of further explanation in advance?
Are the answers consistent?
Are you getting reasoned answers rather than something improvised on the spot?
| What to check | What to look for |
|---|---|
| Explanatory materials | Can you follow the purpose, steps, visit schedule and stages up to consent at a glance? |
| Reasoning on suitability | Beyond the diagnosis, are criteria given that account for symptoms and medical history? |
| Delivery structure | Are roles, testing and post-administration follow-up clearly set out? |
| Process transparency | Are the costs, further explanation and consent form contents clear? |
A perspective for comparing
If you’re looking at several providers, check not only how carefully things are explained but whether the content is internally consistent. A brochure may present a broad range of applications while the actual consultation reveals fairly narrow criteria — whether the materials and the spoken explanation align is an important signal.
Where a regenerative medical product is used, confirming whether it is an approved product and whether indications and conditions of use are defined helps you place it within the regulatory framework. With self-funded care, the same name can mean different methods, so it’s worth comparing the processing and the visit plan too.
In choosing a provider, prioritising clarity on who delivers it, under which framework, and through what steps — rather than striking claims — makes the comparison far more practical.
What to Prepare Before Your Consultation
Rather than recalling things on the spot in the consulting room, pulling your information together beforehand makes it far easier for a doctor to understand your situation. The course of your symptoms and your treatment history in particular tend to form the basis of any judgement.
What to include in your notes
- Course of symptoms — when it started, how it has changed, what triggers worsening or relief
- Medical history — conditions previously identified, surgical history, any allergies
- Treatment history — tests, medications, rehabilitation, injections and surgery, with dates
- Current medications — prescriptions, supplements, topical treatments, over-the-counter drugs
- The goal you’re hoping for — reducing pain, maintaining daily life, continuing work or a hobby
A tip on conveying it
Rather than fine wording, arranging the facts in chronological order communicates best. Even briefly listing “since when,” “in what situations” and “how difficult it is” gives the conversation a clear way in.
Don’t hold back on what’s on your mind either — keeping it as bullet points reduces what gets forgotten. If you struggle to say it in the moment, showing the doctor a note on paper or your phone works perfectly well.
Examples of what to ask
- Given my current state, are further tests or checks needed?
- What factors might be contributing to my current symptoms?
- Is there anything I should be careful about in daily life?
- Now that you know the goal I’m hoping for, what would be a good direction for the next conversation?
With your information organised beforehand, the key points get across even in a short appointment. Being clear about why you’re there, and bringing your questions written down, is the first step towards a conversation you can feel settled about.
Frequently Asked Questions
Regenerative medicine can differ from ordinary insured care in its regulatory framework, eligibility and how costs work. Organising your questions and putting them to a doctor beforehand makes the process easier.
Q1. Under which framework would I be receiving regenerative medicine?
Regenerative medicine covers several situations: clinical research conducted under a national framework, treatment using approved regenerative medical products, and care provided on a self-funded basis. Which framework applies changes the explanation, the procedures and how costs are handled, so confirming which framework the treatment sits under comes first.
Q2. Who is considered eligible?
Eligibility differs by treatment and isn’t decided by diagnosis alone. In most cases suitability is judged from age, severity, past treatment history and test results together. Rather than deciding for yourself based on symptoms or a diagnosis name, confirm it in consultation.
Q3. How should I think about cost?
Out-of-pocket costs work very differently between insured and self-funded care. With self-funded care, testing, collection, processing and visits are sometimes billed separately from the treatment itself. Confirming the approximate total and whether additional charges apply, in writing and in advance, saves uncertainty later.
Q4. How many visits are involved, and over what period?
It varies by treatment, but it rarely ends with the first appointment — collection, administration and follow-up may each require attendance. Since this can affect work and family commitments, confirming the number of visits, the time each takes and how follow-up works makes the decision more realistic.
Q5. Who should I speak to first?
As a rule, start with the doctor already treating you. Working from your existing conditions, current medications and treatment history makes it easier to establish whether regenerative medicine is worth considering and what other options exist. If you go on to look for a referral, check whether the explanation given is thorough and whether questions get careful answers.
Summary and What to Do Next
When considering regenerative medicine, the starting point is confirming which framework it is being provided under. Clinical research, approved treatment and self-funded care can look alike, but their positions differ — and so does what you need to check.
Where regenerative medical products are involved, look past the name and calmly review the conditions treated, the terms of use, the range of what can be expected, and the possible downsides.
Next steps, in order of priority
Speak to your own doctor first
Establish what standard treatment can realistically achieve for your current condition. From there, work out whether adding regenerative medicine to the picture makes sense.
Re-check what you were told
Review whether the purpose, eligibility, collection and administration process, cost, number of visits and follow-up method are all stated specifically. Where the wording is vague, ask rather than letting it stand.
Get a second opinion if needed
If you’re torn, or uneasy about how something was explained, hear another doctor’s view and compare. More than one perspective makes it easier to see which option suits you.
Worth keeping in mind when you consult
- ✓What options are worth considering for my symptoms at this stage?
- ✓If regenerative medicine is proposed, what evidence is the explanation based on?
- ✓How would side effects or complications be handled if they occurred?
- ✓Counting cost and visits, is this something I can sustain without strain?
There’s no need to settle it quickly. Speak to your own doctor, verify the explanation, and if necessary widen the picture with a second opinion. Taken in that order, deciding whether to go ahead becomes much more manageable.
The first thing to do after reading this isn’t to take a treatment name at face value, but to hold its regulatory position up against your own situation and check the two against each other.
Where to Verify Information
When checking the regulation and safety of regenerative medicine, it works best to establish which framework the care sits in via official bodies first, then compare the research stage and reported findings using academic sources. Below is how the Ministry of Health, Labour and Welfare, PMDA, jRCT, PubMed and J-STAGE divide up, alongside what each is useful for.
Ministry of Health, Labour and Welfare (Japan)
The entry point for the Act on the Safety of Regenerative Medicine and for how regenerative medical products and clinical research are regulated. Useful for establishing, at the regulatory level, whether something is approved, research, or self-funded. The Ministry also publishes information on regenerative medicine provision plans and certified review committees — this is where to look if you want to check regenerative medicine offered on a self-funded basis.
PMDA (Pharmaceuticals and Medical Devices Agency)
Useful for checking the approval status, package inserts and safety information for regenerative medical products. Look past the product name to whether the indications and precautions match your own situation.
jRCT (Japan Registry of Clinical Trials)
A way to check whether a study is registered, along with the conditions targeted, primary endpoints and delivery structure. Useful for telling whether care is at the research stage. Note that what jRCT holds is information on clinical research and trials; for regenerative medicine offered as self-funded care, check the provision plan information published by the Ministry of Health, Labour and Welfare.
| Source | Main use | What to check in particular |
|---|---|---|
| Ministry of Health, Labour and Welfare | Establish the regulatory category | Whether the classification of regenerative medicine and the rules on plans and procedures are explained |
| Provision plan information | Check provision status, including self-funded care | Whether a plan has been submitted, and what regenerative medicine it covers (published by the Ministry) |
| PMDA | Check product-level information | Approval status, indications, and whether precautions align with your situation |
| jRCT | Check registered study details (research only) | Research purpose, participants, evaluation method, whether it is ongoing |
| PubMed | Check the evidence in peer-reviewed literature | Sample size, comparison method, limitations, reporting of adverse events |
| J-STAGE | Check Japanese academic journals | Supplementary reading of research in a context closer to Japanese practice and regulation |
What to watch for when reading academic sources
- —Read with a clear sense of whether the report is clinical research, a case report, or basic science
- —Where the sample is small, don’t generalise the findings too far
- —Look for reporting of adverse events and reasons for discontinuation, not just efficacy
- —Where follow-up is short, treat conclusions about the long term as limited
- —Check that a facility’s explanation doesn’t diverge sharply from the literature and registry entries
The order to check things in
Look at regulation and approval status via official bodies first, then confirm who it is for and what is involved via registry information, and read the literature on efficacy and limitations last. Keeping to that order makes promotional language much less likely to pull you along.
Reference sources are most useful not for reaching a conclusion quickly, but for calmly verifying that an explanation holds up. When considering regenerative medicine, comparing regulation, registry and literature side by side — and consulting your own doctor where needed — is the sound approach.
About Ginza YR Clinic
We are a medical practice in Ginza, Tokyo, built around regenerative medicine. Our starting point is “Ageing Well” — not resisting age, but moving through each stage of it in good health and on your own terms. Physicians with specialist qualifications and clinical experience assess each person’s condition as a whole before setting out the options worth considering.
An initial consultation covers an assessment of your current condition, along with an explanation of suitability, what the treatment involves, cost and risk. There’s no need to decide anything on the day.
Start by understanding where you stand, then weigh the options
By appointment only / Self-funded care (outside public health insurance)
Notes and Disclaimer
- This article is intended to provide general medical information. It does not guarantee any specific treatment outcome, nor does it recommend any particular medical institution or treatment.
- Results and recovery vary between individuals.
- The Act on Pharmaceuticals and Medical Devices, the Act on the Safety of Regenerative Medicine, regenerative medical products and self-funded care referred to here are all part of the Japanese regulatory system, and do not map directly onto categories used in other countries.
- Treatments of the kind discussed here are, in most cases, provided as self-funded care in Japan (outside public health insurance), with costs borne in full by the patient.
- Regulatory content and approval status are subject to change. The amending act to the Act on the Safety of Regenerative Medicine was promulgated on 14 June 2024 and came into force on 31 May 2025, extending its scope to include gene therapy that does not use processed cells. Please refer to the official bodies for the latest information.
- For individual diagnosis and to determine whether a treatment is appropriate for you, please consult a physician in person.
Sources: Ministry of Health, Labour and Welfare (Japan); PMDA (Pharmaceuticals and Medical Devices Agency); jRCT (Japan Registry of Clinical Trials); PubMed; J-STAGE
